Mechanistic Insight of Synthesized 1,4-Dihydropyridines as an Antidiabetic Sword against Reactive Oxygen Species by Peter A. Sidhom (14313061)

“…Also, compound <b>8b</b> decreased blood glucose by α-glucosidase inhibition (IC₅₀ = 4.48 ± 0.32 μM), compared to acarbose (7.40 ± 0.41 μM), based selectively on the plasma window of <b>8b</b>. …”

<i>sim-bam-yfp; bam</i>⁻female fertility decreases with additional copies of <i>sim-bam-yfp</i>. by Heather A. Flores (378016)

Excitation frequency decreases as fibroblasts density increases for all fibroblast island sizes (A - 2×2, B - 4×4, C - 6×6). by Ronit V. Oren (234285)

Claudin-18 knockdown by siRNA. (A) Claudin-18 siRNA significantly decreases the mRNA level of claudin-18 in MKN74. by Tadayuki Oshima (461127)

Increased amount of phosphorylated proinflammatory osteopontin in rheumatoid arthritis synovia is associated to decreased tartrate-resistant acid phosphatase 5B/5A ratio by Jani Luukkonen (4339744)

Table 1_A novel α-conotoxin [D1G, ΔQ14] LvIC decreased mouse locomotor activity.xls by Wen Wang (6570)

Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner by Khondoker Alam (1443499)

“…Pretreatment with bortezomib (50–250 nM, 2–7 h) significantly decreased transport of [³H]CCK-8, a specific OATP1B3 substrate, in HEK293-OATP1B3 and human sandwich-cultured hepatocytes (SCH). …”

Bcl-xL protein levels were decreased in response to siRNA transfection in A549, SK-LU1 and NP-69 cells. by Norahayu Othman (495150)

“…<p>(<b>A</b>) Western blot indicating a significant decrease in Bcl-xL protein levels in comparison to non-transfected cells 48 h post-transfection. …”

Total and phosphorylated alpha-synuclein levels are unchanged in the homozygous <i>GBA1</i> D409V KI mouse brain at 12 months of age. by Nicole K. Polinski (10947787)

An example of regional-level GIS outputs derived via the questionnaire data: Collated fisher responses to trends in dugong captures in fishing gear across all recorded years, scale... by Nicolas J. Pilcher (203564)

Comparison of uracil-DNA mediated BER in extracts from WT and WRN KD cells by Jeanine A. Harrigan (14466)

FTY720 potentiated the activity of cisplatin. by Laura L. Stafman (6577184)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Representative diagram shows the impact of TXNIP deletion on retina vasculature under both normoxia and hyperoxia. by Mohammed A. Abdelsaid (287140)

AA and DHA modulate phosphorylation of ERK1/2 in both FXR1-WT and KO macrophages. by Claude Lachance (201669)

“…<p>FXR1-WT (A and C) and FXR1-KO (B and D) macrophage cell lines (1×10⁶ cells) were untreated (Medium) or treated with AA (100 nM) or DHA (100 nM) for 21 h. …”